SD2008-289: G alpha i - GIV Interface as a Novel Therapeutic Target. (Ghosh, Garcia-Marcos, M., and Farquhar, M.G.).
SD2008-289: Tumoral GIV as a novel biomarker for prognostication in carcinomas. (Ghosh, P., Garcia-Marcos, M., and Farquhar, M.G.). Licensed antibody production (for research purpose) with Millipore Inc. Licensing underway (for diagnostics purposes) with Roche Diagnostics.
SD2008-289: GIV as a serum biomarker for metastatic progression of carcinomas. (Ghosh and Garcia-Marcos).
SD2010-066: A Marker and Therapeutic Target for the PI3K Pathway. Licensing completedwith Roche Diagnostics (for diagnostics applications) and with Millipore Inc. (for research applications).
SD2013-019: A Novel Diagnostic and Therapeutic Target within the Wnt Pathway- (Molecular Basis for Aberrant Signal Amplification in Leukemia, Lymphomas, Solid tumors (breast/Colon) during early oncogenesis and during developmental disorders of the brain). Licensed with Millipore Inc. (for research applications).
SD2013-243: Title of Invention A Blood Test to Prognosticate Progression-Free and Overall Survival in Cancer Patients. Licensing underway with a San Diego-based Biotech Company.
SD2014-148: A Method to Predict and Treat Liver Fibrosis and other Fibrogenic Disorders. Licensing underway with Ventana Inc (a branch of Roche Diagnostics).
SD2014-186: G-alpha, interacting vesicle associated protein (giv) as a prognositic in stage ii colorectal cancer. Joint IP with Ventana Inc (a branch of Roche Diagnostics).
SD-2014-259: Detection and Treatment of GIV-associated Cancer.
SD2014-283-1: Method to assemble, visualize and measure RTK-G protein complexes in cells.